Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Genetic Testing|April 1, 2008
Ulna/height ratio as clinical parameter separating EXT1 from EXT2 families?Barbara Leube, Karin Hardt, Sebastian Portier, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2003
Sequences in the (A)gamma-delta intergenic region are not required for stage-specific regulation of the human beta-globin gene locusKarin M L Gaensler, Zemin Zhang, Chin Lin, et al.
Human Vaccines & Immunotherapeutics|April 18, 2012
Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccinationUlrich Behre, Gerhard Bleckmann, Priya Diana Crasta, et al.
Gynecologic Oncology|February 17, 2009
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responsesMarie-Pierre David, Koen Van Herck, Karin Hardt, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|August 7, 2007
Clinical outcome and genotype in patients with hereditary multiple exostosesMarcus Jäger, Bettina Westhoff, Sebastian Portier, et al.
Vaccine|November 27, 2016
Vaccine strategies: Optimising outcomesKarin Hardt, Paolo Bonanni, Susan King, et al.
Vaccine|October 11, 2008
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccinesThomas Verstraeten, Dominique Descamps, Marie-Pierre David, et al.
Human Vaccines & Immunotherapeutics|February 14, 2012
Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancyGiuseppe Ferrera, Mario Cuccia, Gabriele Mereu, et al.
Vaccine|July 2, 2011
Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trialsPierre Van Damme, Peter McIntyre, Emmanuel Grimprel, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 16, 2023
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humansAnna Dari, Philippe Jacqmin, Yuki Iwaki, et al.
Pageof 4